Phase II Study of Pemetrexed and Erlotinib in Pretreated Nonsquamous, Non-Small-Cell Lung Cancer Pat...
Phase II Study of Pemetrexed and Erlotinib in Pretreated Nonsquamous, Non-Small-Cell Lung Cancer Patients without an EGFR mutation
About this item
Full title
Author / Creator
Publisher
Basel, Switzerland: Karger
Journal title
Language
English
Formats
Publication information
Publisher
Basel, Switzerland: Karger
Subjects
More information
Scope and Contents
Contents
Background: Preclinical data indicated that the combination of erlotinib and pemetrexed is synergistic when erlotinib is administered after pemetrexed. Patients and Methods: This was a phase II study of pemetrexed and erlotinib in patients with pretreated advanced non-squamous non-small-cell lung cancer (NSCLC) with wild-type epidermal growth facto...
Alternative Titles
Full title
Phase II Study of Pemetrexed and Erlotinib in Pretreated Nonsquamous, Non-Small-Cell Lung Cancer Patients without an EGFR mutation
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_karger_primary_363731
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_karger_primary_363731
Other Identifiers
ISSN
0009-3157
E-ISSN
1421-9794
DOI
10.1159/000363731
